Brief: Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis
05/06/2025 12:20
Kiniksa Pharmaceuticals International PLC KNSA.O: KINIKSA PHARMACEUTICALS ANNOUNCES TRIAL DESIGN OF PLANNED PHASE 2/3 CLINICAL TRIAL OF KPL-387 IN RECURRENT PERICARDITIS KINIKSA PHARMACEUTICALS INTERNATIONAL PLC - TO INITIATE PHASE 2/3 TRIAL OF KPL-387 IN MID-2025 KINIKSA PHARMACEUTICALS INTERNATIONAL PLC: KPL-387 PHASE 2 DATA EXPECTED IN 2H 2026 Source text: ID:nGNXbqNj3Y Further company coverage: KNSA.O
Recent news on Kiniksa Pharmaceuticals International
See all newsKiniksa Pharmaceuticals International, PLC expected to post earnings of 37 cents a share - Earnings Preview
Kiniksa Pharmaceuticals International, PLC reports results for the quarter ended June 30 - Earnings Summary
Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales
Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a share - Earnings Preview
Cardiovascular drugmaker Kiniksa's Q1 net income rises